High bone mass from mutation of low-density lipoprotein receptor-related protein 6 (LRP6).

Albers-Schönberg disease Bone modeling Creatine kinase DXA Endosteum Exostosis Hyperostosis LRP5 LRP6 Lactate dehydrogenase Mutation Osteopetrosis Osteosclerosis Sclerostin Skeletal dysplasia Torus palatinus Wnt signaling β-catenin

Journal

Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048

Informations de publication

Date de publication:
12 2020
Historique:
received: 17 06 2020
accepted: 04 07 2020
pubmed: 31 7 2020
medline: 22 6 2021
entrez: 31 7 2020
Statut: ppublish

Résumé

Wnt/β-catenin signaling is important for skeletal development and health. Eleven heterozygous gain-of-function missense mutations within the first β-propeller of low-density lipoprotein receptor-related protein 5 (LRP5) are known to cause the autosomal dominant disorder called high bone mass (HBM). In 2019, different heterozygous LRP6 missense mutations were identified in two American families with the HBM phenotype but including absent lateral maxillary and mandibular incisors. We report a 19-year-old Argentinian man referred for "osteopetrosis" and nine years of generalized, medium-intensity bone pain and arthralgias of both knees. His jaw and nasal bridge were broad and several teeth were missing. Routine biochemical testing, including of mineral homeostasis, was normal. Urinary deoxypyridinoline and serum CTX were slightly increased. Radiographic skeletal survey showed diffusely increased radiodensity. DXA revealed substantially elevated BMD Z-scores. Digital orthopantomography confirmed agenesis of his maxillary and mandibular lateral incisors and his second left superior premolar. Cranial magnetic resonance imaging showed diffuse thickening of the calvarium and skull base, dilation of the sheath of the optic nerves containing increased fluid and associated with subtle stenosis of the optic canal, and narrow internal auditory canals. Mutation analyses identified a heterozygous indel mutation in exon 4 of LRP6 involving a single nucleotide change and 6-nucleotide deletion (c.678T>Adel679-684, p.His226Gln-del227-228ProPhe) leading to a missense change and 2-amino acid deletion that would compromise the first β-propeller of LRP6. Experience to date indicates LRP6 HBM is indistinguishable from LRP5 HBM without mutation analysis, although in LRP6 HBM absence of adult lateral incisors may prove to be a unique feature.

Identifiants

pubmed: 32730923
pii: S8756-3282(20)30330-6
doi: 10.1016/j.bone.2020.115550
pii:
doi:

Substances chimiques

LRP6 protein, human 0
Low Density Lipoprotein Receptor-Related Protein-6 0

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

115550

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

María Lorena Brance (ML)

Reumatología y Enfermedades Óseas, Rosario, Argentina; Bone Biology Laboratory, School of Medicine, Rosario National University, Argentina; National Council of Scientific and Technical Research (CONICET), Argentina. Electronic address: laboratorio@biologiaosea.com.ar.

Lucas R Brun (LR)

Bone Biology Laboratory, School of Medicine, Rosario National University, Argentina; National Council of Scientific and Technical Research (CONICET), Argentina. Electronic address: lbrun@unr.edu.ar.

Nicolás M Cóccaro (NM)

Servicio de Diagnóstico por Imágenes, Sanatorio Británico, Rosario, Argentina.

Andrés Aravena (A)

Bone Biology Laboratory, School of Medicine, Rosario National University, Argentina.

Shenghui Duan (S)

Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children, St. Louis, MO, USA. Electronic address: sduan@wustl.edu.

Steven Mumm (S)

Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children, St. Louis, MO, USA; Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine at Barnes-Jewish Hospital, St. Louis, MO, USA. Electronic address: smumm@wustl.edu.

Michael P Whyte (MP)

Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children, St. Louis, MO, USA; Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine at Barnes-Jewish Hospital, St. Louis, MO, USA. Electronic address: mwhyte@shrinenet.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH